APSR2026-638

 
Late-Breaking
Submitted
Poster Presentation
 
AP14-058
P77
 
Format: PPTX Only
https://storage.unitedwebnetwork.com/files/1285/1221015-46904-Successful combination of chemotherapy and immunotherapy in advanced squamous cell lung carcinoma a case report (5)_434943.pdf
Format: PDF Only
08. Lung Cancer
2

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

Rahayu Asmarani * Faculty of Health Sciences Lambung Mangkurat University, Department of Pulmonology and Respiratory Medicine/Oncology Thorax Division Banjarmasin Indonesia
Erna Kusumawardhani - Faculty of Health Sciences Lambung Mangkurat University/ Department of Pulmonology and Respiratory Medicine Banjarmasin Indonesia
 
 
 
 
 
 
 
 
 
 
 
 
 
Presenting Author Details
Rahayu
Asmarani
rahayu.asmarani2901@gmail.com
+6285235322181
31-40
Indonesia
Case Report
Successful combination of chemotherapy and immunotherapy in advanced squamous cell lung carcinoma: a case report
Maximum 25 words
Abstract Content
 
 
 
 
Squamous cell carcinoma (SCC) is a major subtype of non-small cell lung cancer (NSCLC) and is often diagnosed at an advanced stage, thereby limiting curative treatment options. In the Asia-Pacific region, including Indonesia, lung cancer remains the leading cause of cancer-related mortality, with most patients presenting at advanced stages and a 5-year survival rate of <10–15%. Immune checkpoint inhibitors combined with platinum-based chemotherapy are the standard first-line treatment; however, real-world data from regional settings remain limited.
A 42-year-old heavy-smoking male presented with chronic hemoptysis and left-sided chest pain. Thoracic CT showed a left lung mass with mediastinal lymphadenopathy and metastases to the adrenal gland and vocal cord, consistent with stage IVB disease. Histopathology confirmed SCC. Laboratory findings revealed elevated tumour markers and malignant hypercalcemia (11.4 mg/dL). Due to limited access, programmed death-ligand 1 (PD-L1) testing was not performed. Nevertheless, the patient demonstrated a positive clinical response. First-line carboplatin–paclitaxel combined with serplulimab was initiated. Hypercalcemia was treated with zoledronic acid. After three cycles, treatment was well tolerated, with improvement in symptoms and performance status (ECOG 2 to 1), no significant immune-related adverse events, and 8.1% tumour reduction with resolution of ground-glass opacity.
Chemo-immunotherapy improves outcomes in advanced squamous NSCLC. The phase III ASTRUM-005 trial demonstrated that serplulimab plus chemotherapy improved overall survival (15.4 vs 11.9 months) and progression-free survival (5.7 vs 4.3 months), regardless of PD-L1 expression. In this case, the regimen showed good tolerance and clinical benefit. Zoledronic acid effectively managed malignant hypercalcemia, highlighting the importance of comprehensive oncologic care. This case demonstrates that the combination of platinum-based chemotherapy and serplulimab is a feasible and safe first-line treatment for advanced squamous cell lung carcinoma in a regional clinical setting, providing crucial real-world evidence that high-standard chemo-immunotherapy can be successfully implemented despite local logistical challenges.
 
 
No
No
 
JPG or JPEG or PNG format ONLY
Squamous cell lung carcinoma; Chemotherapy; Immunotherapy
maximum 3 keywords and no abbreviations, separated by commas
The authors declare no conflicts of interest. No financial support was received for this study. We thank the patients and their families for consenting to participate in this case report.
303